aTyr Pharma Revenue and Competitors

Location

$331.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • aTyr Pharma's estimated annual revenue is currently $14.4M per year.(i)
  • aTyr Pharma's estimated revenue per employee is $155,000
  • aTyr Pharma's total funding is $331.8M.

Employee Data

  • aTyr Pharma has 93 Employees.(i)
  • aTyr Pharma grew their employee count by -7% last year.

aTyr Pharma's People

NameTitleEmail/Phone
1
VP Corporate DevelopmentReveal Email/Phone
2
VP, Human ResourcesReveal Email/Phone
3
VP FinanceReveal Email/Phone
4
VP External Scientific Alliances and Intellectual PropertyReveal Email/Phone
5
General CounselReveal Email/Phone
6
VP, ResearchReveal Email/Phone
7
VP, Regulatory AffairsReveal Email/Phone
8
VP Clinical OperationsReveal Email/Phone
9
Senior DirectorReveal Email/Phone
10
Associate DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31800M1095784%$367M$146B
Add Company

What Is aTyr Pharma?

aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and clinical development of innovative medicines based on novel immunological pathways. We have concentrated our research and development efforts on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. We have built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. We are focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family, one of the synthetase genes. ATYR1923 is a clinical-stage product candidate, based on the Resokine pathway, which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.

keywords:N/A

$331.8M

Total Funding

93

Number of Employees

$14.4M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

aTyr Pharma News

2022-04-19 - ATYR PHARMA INC : Entry into a Material Definitive ...

ATYR PHARMA INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and...

2022-03-30 - aTyr Pharma to Present Clinical Data for Efzofitimod ...

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's...

2022-03-22 - aTyr Pharma Announces Inducement Grants Under Nasdaq ...

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr's...

2021-11-11 - ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update - Form 8-K

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registration ...

2021-11-11 - ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initiate in 2022. Se ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.3M9311%N/A
#2
$25.1M934%N/A
#3
$25.1M936%N/A
#4
$7.5M9322%N/A
#5
$27M93-3%N/A